Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xiidra in dry eye disease
NCT03952481Phase 4Withdrawn
- Sponsor
- Weill Cornell Medicine
- Start
- Mar 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-blind trial of lifitegrast in dry eye disease (DED), sponsored by Weill Cornell Medicine. Primary endpoint: Tear film osmolarity at 4 weeks. Planned start Mar 2021; status: withdrawn.
02
Drugs
lifitegrast
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT03952481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03952481.